<![CDATA[Alecensa Improves 4-Year Survival in Early ALK-Positive Lung Cancer]]>
Adjuvant treatment with Alecensa (alectinib) elicited a 4-year overall survival (OS) rate of 98.4% for patients with resected ALK-positive early stage non–small cell lung cancer (NSCLC) according to an updated analysis of the phase 3 ALINA study presented …